BioVaxys Technology Corp.
BioVaxys Technology Corp.
Indice CSE:
Devise:
BioVaxys Technology Corp. is a British Columbia-registered biopharmaceuticals company based in Ontario, Canada that is developing BVX-0918, a personalized immunotherapeutic vaccine using our proprietary HapTenix© 'neoantigen' tumor cell construct platform for treating refractive late stage ovarian cancer. BioVaxys is also exploring vaccines for additional cancers and infectious diseases based on its HapTenix©platform through academic and other collaborations.
BioVaxys Technology Corp. (BIOV)
SEDAR Information
Information d'entreprise
Addresse
146 Thirtieth Street
Suite 100
Etobicoke, ON M8W 3C4
CanadaTéléphone
646-452-7000Courriel
jpassin@biovaxys.comURL
https://biovaxys.com/Date d’inscription à la cote
Mercredi, novembre 21, 2018
Agent de transfert
Odyssey Trust CompanyCourriel
news@biovaxys.comVérificateur
Dale Matheson Carr-Hilton Labonte LLPCapitalisation
Capitalisation:
262058498Réservé à l'émission:
117371153Company Officers
James Passin, CEO
Kenneth Kovan, COO & President
Christopher Cherry, Chief Financial Officer
James Passin, Chief Executive Officer
Christopher Cherry, Chief Financial Officer
Kenneth Kovan, Chief Operating Officer and President
Bulletins
Dépôts CSE
